Study discontinued as DSMB determined it was futile. No safety concerns were noted.

This is a Phase 3 study to evaluate posoleucel (ALVR105, Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus.

This is a Phase 2/3, multicenter, randomized, double-blind, placebo controlled trial comparing posoleucel to placebo for the prevention of infection or disease due to AdV, BKV, CMV, EBV, HHV-6, or JCV in high-risk adult and pediatric patients after allogeneic HCT.

There are 2 parts to the study, a Phase 3 randomized study cohort described in this posting, and an open label Phase 2 cohort described in NCT04693637, which has completed enrollment. In this Phase 3 part, approximately 302 eligible allogeneic HCT recipients will be enrolled and will receive 7 doses of posoleucel or placebo over 12 weeks, followed by a 12 week follow-up period.

Key Inclusion Criteria:

• Any age at the day of screening visit.

• No known or suspected clinically significant disease from AdV, BKV, CMV, EBV, HHV-6, and/or JCV

• Within 25 days of receiving a first allogeneic HCT and have demonstrated clinical engraftment at time of dosing

• Meet one or more of the following criteria at the time of randomization:

  • Related (sibling) donor with at least one mismatch at one of these HLA-gene loci: HLA-A, -B or -DR
  • Haploidentical donor
  • Matched or Mismatched unrelated donor
  • Use of umbilical cord blood as stem cell source
  • Ex vivo graft manipulation resulting in T cell depletion
  • Received anti-thymocyte globulin or alemtuzumab (Campath-1H)

Key Exclusion Criteria:

• History of AdV, BKV, CMV, EBV, HHV-6, and/or JCV end-organ disease within 6 months prior to randomization
• Evidence of active Grade >2 acute GVHD
• Presence of non-minor uncontrolled or progressive bacterial, viral or fungal infections
• Known history or current (suspected) diagnosis of Grade ≥3 CRS requiring treatment associated with the administration of peptides, proteins, and/or antibodies
• Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone equivalent dose >1.0 mg/kg/day) within 24 hours prior to dosing
• Relapse of primary malignancy other than minimal residual disease

Note: Other protocol defined Inclusion/Exclusion criteria may apply.